Table VI.
Clinical characteristics of patients according to their treatment modalities before and after the decrease of HbA1c levels
| Parameters | Before | After | P-value |
|---|---|---|---|
| HbA1c (%) (OAD) | 8.50 ±1.57 | 6.89 ±0.97 | < 0.001 |
| HbA1c (%) (INS) | 10.18 ±2.00 | 7.87 ±1.36 | < 0.001 |
| FBG [mmol/l] (OAD) | 10.08 ±3.45 | 7.66 ±1.80 | < 0.001 |
| FBG [mmol/l] (INS) | 13.40 ±4.91 | 9.06 ±3.14 | < 0.001 |
| PPG [mmol/l] (OAD) | 13.88 ±5.19 | 10.63 ±3.52 | < 0.001 |
| PPG [mmol/l] (INS) | 18.42 ±5.14 | 13.51 ±5.38 | < 0.001 |
| MPV [µm3] (OAD) | 9.01 ±1.36 | 8.13 ±1.06 | < 0.001 |
| MPV [µm3] (INS) | 9.22 ±1.47 | 8.21 ±1.03 | < 0.001 |
| Platelets [× 109/l] (OAD) | 265.61 ±61.90 | 270.22 ±66.93 | 0.070 |
| Platelets [× 109/l] (INS) | 241.22 ±56.85 | 250.11 ±59.66 | < 0.001 |
OAD – oral antidiabetic drugs, INS – insulin.